RT Journal Article
SR Electronic
T1 Accelerometer-derived sleep onset timing and cardiovascular disease incidence: a UK Biobank cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.23.21259390
DO 10.1101/2021.06.23.21259390
A1 Nikbakhtian, Shahram
A1 Reed, Angus B
A1 Obika, Bernard Dillon
A1 Morelli, Davide
A1 Cunningham, Adam C
A1 Aral, Mert
A1 Plans, David
YR 2021
UL http://medrxiv.org/content/early/2021/06/28/2021.06.23.21259390.abstract
AB Aims Growing evidence suggests that sleep quality is associated with cardiovascular risk. However, research in this area often relies upon recollection dependant questionnaires or diaries. Accelerometers provide an alternative tool for deriving sleep parameters measuring sleep patterns objectively. This study examines the associations between accelerometer derived sleep onset timing and cardiovascular disease (CVD).Methods and Results We derived sleep onset and waking up time from accelerometer data collected from 103,712 UK Biobank participants over a period of seven days. From this, we examined the association between sleep onset timing and CVD incidence using a series of Cox proportional hazards models. 3172 cases of CVD were reported during a mean follow-up period of 5·7 (±0·49) years. An age- and sex-controlled base analysis found that sleep onset time of 10:00pm-10:59pm was associated with the lowest CVD incidence. A fully adjusted model, additionally controlling for sleep duration, sleep irregularity, and established CVD risk factors, was unable to eliminate this association, producing hazard ratios of 1·24 (95% CI, 1·10–1·39; p<0·005), 1·12 (1·01–1·25; p=0·04), and 1·25 (1·02–1·52; p=0·03) for sleep onset <10:00pm, 11:00pm-11:59pm, and ≥12:00am, respectively, compared to 10:00pm-10:59pm. Importantly, sensitivity analyses revealed this association was stronger in females, with only sleep onset <10:00pm significant for males.Conclusions Our findings suggest an independent relationship between sleep onset timing and risk of developing CVD, particularly for women. We also demonstrate the potential utility of collecting information about sleep parameters via accelerometry-capable wearable devices, which may serve as novel cardiovascular risk indicators.Translational Perspective Abnormal sleep timing is a feature of poor-quality sleep and is likely to be associated with cardiovascular diseases. Accelerometer-derived measures of sleep quality, particularly sleep timing, may be associated with greater vulnerability to cardiovascular disease, particularly in women. Onset of sleep timing may constitute a novel cardiovascular risk factor and target for preventative intervention. Wearable devices equipped with accelerometers may be useful in assessing sleep related cardiovascular disease risk factors as they would allow passive measurement of sleep parameters, such as sleep timing.Competing Interest StatementSN, ABR, ACC, BDO, MA, DM and DP are employees of Huma TherapeuticsFunding StatementThis work was funded by Huma Therapeutics LtdAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants provided informed consent, and the UKB study received ethical approval from the North West Multi-Centre Research Ethics Committee (REC reference: 16/NW/0382) and was conducted in accordance with the principles of the Declaration of Helsinki. The current analyses were conducted under UKB application number 55668. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective intervenxtional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe UKB dataset was obtained from the UKB (application number 55668). Data cannot be shared publicly owing to the violation of patient privacy and the absence of informed consent for data sharing.